首页> 美国卫生研究院文献>NPJ Primary Care Respiratory Medicine >An accurate prediction model to identify undiagnosed at-risk patients with COPD: a cross-sectional case-finding study
【2h】

An accurate prediction model to identify undiagnosed at-risk patients with COPD: a cross-sectional case-finding study

机译:准确的预测模型可识别出未诊断出的COPD高危患者:横断面病例调查研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Underuse or unavailability of spirometry is one of the most important factors causing underdiagnosis of COPD. We reported the development of a COPD prediction model to identify at-risk, undiagnosed COPD patients when spirometry was unavailable. This cross-sectional study enrolled subjects aged ≥40 years with respiratory symptoms and a smoking history (≥20 pack-years) in a medical center in two separate periods (development and validation cohorts). All subjects completed COPD assessment test (CAT), peak expiratory flow rate (PEFR) measurement, and confirmatory spirometry. A binary logistic model with calibration (Hosmer-Lemeshow test) and discrimination (area under receiver operating characteristic curve [AUROC]) was implemented. Three hundred and one subjects (development cohort) completed the study, including non-COPD (154, 51.2%) and COPD cases (147; stage I, 27.2%; II, 55.8%; III–IV, 17%). Compared with non-COPD and GOLD I cases, GOLD II-IV patients exhibited significantly higher CAT scores and lower lung function, and were considered clinically significant for COPD. Four independent variables (age, smoking pack-years, CAT score, and percent predicted PEFR) were incorporated developing the prediction model, which estimated the COPD probability (PCOPD). This model demonstrated favorable discrimination (AUROC: 0.866/0.828; 95% CI 0.825–0.906/0.751–0.904) and calibration (Hosmer-Lemeshow P = 0.332/0.668) for the development and validation cohorts, respectively. Bootstrap validation with 1000 replicates yielded an AUROC of 0.866 (95% CI 0.821–0.905). A PCOPD of ≥0.65 identified COPD patients with high specificity (90%) and a large proportion (91.4%) of patients with clinically significant COPD (development cohort). Our prediction model can help physicians effectively identify at-risk, undiagnosed COPD patients for further diagnostic evaluation and timely treatment when spirometry is unavailable.
机译:肺活量测定仪的使用不足或不可用是导致COPD诊断不足的最重要因素之一。我们报告了COPD预测模型的发展,该模型可在无法使用肺活量测定法时识别高危,未诊断的COPD患者。这项横断面研究在两个单独的时期(发育和验证队列)在医疗中心招募了年龄≥40岁且患有呼吸道症状和吸烟史(≥20包年)的受试者。所有受试者均完成了COPD评估测试(CAT),呼气峰值流速(PEFR)测量和确诊肺活量测定。实现了具有校准(Hosmer-Lemeshow检验)和辨别力(接收器工作特性曲线[AUROC]下的面积)的二元逻辑模型。 301名受试者(发展队列)完成了研究,其中包括非COPD(154,51.2%)和COPD病例(147; I期,27.2%; II,55.8%; III–IV,17%)。与非COPD和GOLD I病例相比,GOLD II-IV患者表现出明显更高的CAT评分和更低的肺功能,并且被认为对COPD具有临床意义。纳入四个独立变量(年龄,吸烟包装年数,CAT分数和预测的PEFR百分比),以开发预测模型,从而估计出COPD概率(PCOPD)。该模型分别为开发和验证队列提供了良好的区分度(AUROC:0.866 / 0.828; 95%CI 0.825-0.906 / 0.751-0.904)和校准(Hosmer-Lemeshow P = 0.332 / 0.668)。使用1000个重复进行的Bootstrap验证得出的AUROC为0.866(95%CI为0.821-0.905)。 PCOPD≥0.65可以识别出具有高特异性(90%)的COPD患者,并且在临床上具有重要意义的COPD(发育队列)的患者中占很大比例(91.4%)。我们的预测模型可以帮助医生有效地识别风险高,未被诊断的COPD患者,以便在无法进行肺活量测定时进一步诊断评估并及时治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号